pantoprazole has been researched along with Esophagitis, Reflux in 70 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 9.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 9.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| ": Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease." | 9.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 9.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 7.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "Gastroesophageal reflux disease (GERD) in primary care practice presents symptomatically, and resources to distinguish promptly between erosive esophagitis and endoscopy-negative reflux disease (ENRD) are limited." | 6.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 6.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| "Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life." | 5.36 | [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease]. ( Gillessen, A, 2010) |
| "The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy." | 5.14 | Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009) |
| "This post-hoc analysis used data from the maintenance phase of the EXPO study (AstraZeneca study code: SH-NEG-0008); 2766 patients with healed reflux oesophagitis and resolved heartburn received once-daily esomeprazole 20 mg or pantoprazole 20 mg for 6 months." | 5.14 | Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009) |
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 5.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 5.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| "Patients with symptoms of gastro-oesophageal reflux disease and endoscopically confirmed erosive oesophagitis at baseline were randomized to receive esomeprazole 40 mg or pantoprazole 40 mg for up to 8 weeks." | 5.11 | Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. ( Adler, J; Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease." | 5.10 | Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. ( Bochenek, W; DeVault, K; Kovacs, TO; Miska, D; Wilcox, CM, 2002) |
| ": Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease." | 5.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "To compare the efficacy and tolerability of pantoprazole 40 mg and omeprazole MUPS 40 mg in patients with moderate to severe gastroesophageal reflux disease (GERD)." | 5.10 | Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. ( Bohuschke, M; Costa Neves, B; Fumagalli, I; Gatz, G; Körner, T; Schütze, K; van Leendert, RJ, 2003) |
| "The aim of this study was to compare the efficacy and tolerability of low dose pantoprazole (20 mg) (a gastric proton pump inhibitor) with standard dose ranitidine (300 mg) (a histamine-receptor antagonist), in their ability to relieve symptoms and heal oesophageal lesions associated with gastrooesophageal reflux disease (GORD)." | 5.09 | Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. ( Bethke, T; de K Grundling, H; Fischer, R; O'Keefe, SJ; Retief, FJ; Theron, I; van Rensburg, CJ; van Zyl, JH, 2000) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 5.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| "The aim of this dose-response study was to compare the effectiveness of 10 mg, 20 mg, and 40 mg of pantoprazole with that of placebo tablets in the healing and symptom relief of gastroesophageal reflux disease associated with erosive esophagitis, and to determine the optimal dose." | 5.09 | Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. ( Bochenek, W; Richter, JE, 2000) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| "Following healing of endoscopically confirmed peptic ulcer or reflux oesophagitis during 4-12 weeks' treatment with pantoprazole (40-80 mg/day), adult patients received open-label maintenance treatment with pantoprazole (40-160 mg/day) for up to 15 years in a single centre combined study (10-year initial study; 5-year extension study)." | 3.78 | Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. ( Athmann, C; Brunner, G; Schneider, A, 2012) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 3.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "A daily eDiary captured 5 individual GERD symptoms." | 2.75 | Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. ( Baker, R; Baker, SS; Comer, GM; Li, H; Maguire, MK; Rath, N; Tsou, VM; Tung, J; Wang, W, 2010) |
| " It is safe to give pantoprazole intravenously and continuously for treatment of severe erosive esophagitis." | 2.73 | A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. ( Barrie, M; Cai, Q; Olejeme, H; Rosenberg, MD, 2008) |
| "Pantoprazole was safe and well tolerated." | 2.71 | Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. ( Delgado, J; Dibildox, M; Gonzalez, J; Madrazo-de la Garza, A; Vargas, A; Yañez, P, 2003) |
| "Gastroesophageal reflux disease (GERD) in primary care practice presents symptomatically, and resources to distinguish promptly between erosive esophagitis and endoscopy-negative reflux disease (ENRD) are limited." | 2.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion." | 2.69 | Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. ( Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999) |
| "Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile." | 2.69 | Pantoprazole versus omeprazole in the treatment of reflux esophagitis. ( Horvat, D; Ivandić, A; Jurisić-Orzen, D; Kotromanović, Z; Maksimović, Z; Males, J; Mandić, B; Nedić, P; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A; Vladika, I; Vranjes, Z, 1999) |
| "Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K(+)-ATPase." | 2.68 | A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. ( Herz, R; Hölscher, AH; Mössner, J; Schneider, A, 1995) |
| "Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+-ATPase." | 2.68 | Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. ( Bethke, TD; Botha, JF; Cariem, AK; Eloff, FP; Grundling, HD; Honiball, PJ; Marks, IN; Segal, I; Simjee, AE; Spies, SK; Theron, I; van Rensburg, CJ; van Zyl, JH, 1996) |
| "Pantoprazole is a new substituted benzimidazole which inhibits gastric H+,K(+)-ATPase." | 2.68 | Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. ( Belaïche, J; Colin, R; Corinaldesi, R; Geldof, H; Maier, C; Valentini, M, 1995) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 2.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| " Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment." | 2.41 | Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. ( Trépanier, EF, 2000) |
| "Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief." | 1.38 | Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. ( Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B, 2012) |
| "Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life." | 1.36 | [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease]. ( Gillessen, A, 2010) |
| "Gastro-oesophageal reflux is the third most frequent cause of chronic cough." | 1.35 | Chronic cough--about a clinical case... ( Fonseca, G, 2009) |
| "Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically." | 1.33 | Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. ( Cao, H; Hu, ZQ; Ikejima, T; Sun, LX; Wang, MW; Zhao, WH, 2005) |
| "Gastroesophageal reflux disease (GERD) has evolved from a scarcely reported, little understood disease process just a century ago to a now highly prevalent disease with up to 25% of the population complaining of symptoms of reflux." | 1.32 | GERD 2003: issues from the past and a consensus for the future. ( Kidd, M; Modlin, I, 2004) |
| "Both acid and bile reflux is significantly suppressed by proton pump inhibitor therapy with exceptions among individual esophagitis patients." | 1.31 | Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. ( Menges, M; Müller, M; Zeitz, M, 2001) |
| "Gastroesophageal reflux disease has a multifactorial etiology." | 1.31 | Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. ( Gadenstaetter, M; Klaus, A; Klingler, PJ; Obrist, P; Profanter, C; Weiss, H; Wetscher, GJ; Wykypiel, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (21.43) | 18.2507 |
| 2000's | 42 (60.00) | 29.6817 |
| 2010's | 13 (18.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lechien, JR | 1 |
| Finck, C | 1 |
| Huet, K | 1 |
| Khalife, M | 1 |
| Fourneau, AF | 1 |
| Delvaux, V | 1 |
| Piccaluga, M | 1 |
| Harmegnies, B | 1 |
| Saussez, S | 1 |
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Mönnikes, H | 1 |
| Schwan, T | 1 |
| van Rensburg, C | 2 |
| Straszak, A | 1 |
| Theek, C | 1 |
| Lühmann, R | 4 |
| Sander, P | 1 |
| Tholen, A | 1 |
| Dunbar, KB | 1 |
| Agoston, AT | 1 |
| Odze, RD | 1 |
| Huo, X | 1 |
| Pham, TH | 1 |
| Cipher, DJ | 1 |
| Castell, DO | 1 |
| Genta, RM | 1 |
| Souza, RF | 1 |
| Spechler, SJ | 1 |
| Law, JK | 1 |
| Andrews, CN | 1 |
| Enns, R | 1 |
| Labenz, J | 3 |
| Armstrong, D | 4 |
| Zetterstrand, S | 2 |
| Eklund, S | 3 |
| Leodolter, A | 2 |
| Chen, WY | 1 |
| Chang, WL | 2 |
| Tsai, YC | 1 |
| Cheng, HC | 2 |
| Lu, CC | 1 |
| Sheu, BS | 2 |
| Brigas, D | 1 |
| Fonseca, G | 1 |
| Baker, R | 1 |
| Tsou, VM | 1 |
| Tung, J | 1 |
| Baker, SS | 1 |
| Li, H | 1 |
| Wang, W | 1 |
| Rath, N | 1 |
| Maguire, MK | 1 |
| Comer, GM | 1 |
| Gillessen, A | 4 |
| Kindt, S | 1 |
| Imschoot, J | 1 |
| Tack, J | 1 |
| Yeh, YC | 1 |
| Masharova, AA | 1 |
| Ianova, OB | 1 |
| Valitova, ÉR | 1 |
| Kim, VA | 1 |
| Zelenkin, SA | 1 |
| Brunner, G | 1 |
| Athmann, C | 1 |
| Schneider, A | 7 |
| Cho, YK | 1 |
| Choi, MG | 1 |
| Bak, YT | 1 |
| Rhee, PL | 1 |
| Kim, SG | 1 |
| Jung, HY | 1 |
| Seol, SY | 1 |
| Bytzer, P | 1 |
| van Zanten, SV | 1 |
| Mattsson, H | 1 |
| Wernersson, B | 1 |
| Kovacs, TO | 1 |
| Wilcox, CM | 1 |
| DeVault, K | 1 |
| Miska, D | 1 |
| Bochenek, W | 2 |
| Leitner, A | 1 |
| Zöllner, P | 1 |
| Frazzoni, M | 1 |
| De Micheli, E | 1 |
| Grisendi, A | 1 |
| Savarino, V | 1 |
| Madrazo-de la Garza, A | 1 |
| Dibildox, M | 1 |
| Vargas, A | 1 |
| Delgado, J | 1 |
| Gonzalez, J | 1 |
| Yañez, P | 1 |
| Körner, T | 1 |
| Schütze, K | 2 |
| van Leendert, RJ | 1 |
| Fumagalli, I | 2 |
| Costa Neves, B | 1 |
| Bohuschke, M | 1 |
| Gatz, G | 1 |
| Pilotto, A | 2 |
| Leandro, G | 2 |
| Franceschi, M | 2 |
| Modlin, I | 1 |
| Kidd, M | 1 |
| Wang, CH | 1 |
| Wang, LX | 1 |
| Yang, Z | 1 |
| Chen, SQ | 1 |
| Zhu, H | 1 |
| Lu, YP | 1 |
| Härtter, S | 1 |
| Connemann, B | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Sachse, J | 1 |
| Hiemke, C | 1 |
| Calleja, JL | 1 |
| Suarez, M | 1 |
| De Tejada, AH | 1 |
| Navarro, A | 1 |
| Cao, H | 1 |
| Wang, MW | 1 |
| Sun, LX | 1 |
| Ikejima, T | 1 |
| Hu, ZQ | 1 |
| Zhao, WH | 1 |
| Lauritsen, K | 1 |
| Katelaris, P | 1 |
| Schmidt, S | 1 |
| Wallner, G | 2 |
| Juergens, H | 1 |
| Preiksaitis, H | 1 |
| Keeling, N | 1 |
| Nauclér, E | 1 |
| Adler, J | 1 |
| Perri, F | 1 |
| Schöffel, L | 1 |
| Naumburger, A | 1 |
| Edwards, SJ | 1 |
| Lind, T | 1 |
| Lundell, L | 1 |
| Pratha, V | 1 |
| Hogan, DL | 1 |
| Lynn, RB | 2 |
| Field, B | 1 |
| Metz, DC | 2 |
| Rogart, JN | 1 |
| Siddiqui, UD | 1 |
| DeVault, KR | 1 |
| Morgenstern, DM | 1 |
| Cai, Q | 1 |
| Barrie, M | 1 |
| Olejeme, H | 1 |
| Rosenberg, MD | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Mössner, J | 2 |
| Hölscher, AH | 1 |
| Herz, R | 1 |
| Koop, H | 2 |
| Schepp, W | 1 |
| Dammann, HG | 1 |
| Classen, M | 1 |
| Wilson, BV | 1 |
| Knudsen, T | 1 |
| van Rensburg, CJ | 3 |
| Honiball, PJ | 2 |
| Grundling, HD | 2 |
| van Zyl, JH | 3 |
| Spies, SK | 2 |
| Eloff, FP | 2 |
| Simjee, AE | 2 |
| Segal, I | 1 |
| Botha, JF | 1 |
| Cariem, AK | 1 |
| Marks, IN | 1 |
| Theron, I | 3 |
| Bethke, TD | 1 |
| Corinaldesi, R | 1 |
| Valentini, M | 1 |
| Belaïche, J | 1 |
| Colin, R | 1 |
| Geldof, H | 2 |
| Maier, C | 3 |
| Lamers, CB | 1 |
| Armbrecht, U | 1 |
| Abucar, A | 1 |
| Hameeteman, W | 1 |
| Stockbrügger, RW | 1 |
| Porst, H | 1 |
| Wübbolding, H | 1 |
| Dettmer, A | 1 |
| Vogt, R | 1 |
| Sielaff, F | 1 |
| Fischer, R | 5 |
| Holtmann, G | 1 |
| Cain, C | 1 |
| Malfertheiner, P | 1 |
| Louw, JA | 1 |
| Escourrou, J | 1 |
| Deprez, P | 1 |
| Saggioro, A | 1 |
| Vcev, A | 1 |
| Stimac, D | 1 |
| Vceva, A | 1 |
| Takac, B | 1 |
| Ivandić, A | 1 |
| Pezerović, D | 1 |
| Horvat, D | 1 |
| Nedić, P | 1 |
| Kotromanović, Z | 1 |
| Maksimović, Z | 1 |
| Vranjes, Z | 1 |
| Males, J | 1 |
| Jurisić-Orzen, D | 1 |
| Vladika, I | 1 |
| Stimac, T | 1 |
| Mandić, B | 1 |
| de K Grundling, H | 1 |
| Retief, FJ | 1 |
| O'Keefe, SJ | 1 |
| Bethke, T | 1 |
| Plein, K | 1 |
| Hotz, J | 1 |
| Wurzer, H | 1 |
| Richter, JE | 1 |
| Trépanier, EF | 1 |
| Menges, M | 1 |
| Müller, M | 1 |
| Zeitz, M | 1 |
| Bardou, M | 1 |
| Dupas, JL | 1 |
| Houcke, P | 1 |
| Samoyeau, R | 1 |
| Adamek, RJ | 1 |
| Behrendt, J | 1 |
| Wenzel, C | 1 |
| Bardhan, KD | 1 |
| Wetscher, GJ | 1 |
| Gadenstaetter, M | 1 |
| Klingler, PJ | 1 |
| Weiss, H | 1 |
| Obrist, P | 1 |
| Wykypiel, H | 1 |
| Klaus, A | 1 |
| Profanter, C | 1 |
| Paré, P | 1 |
| Pericak, D | 1 |
| Pyzyk, M | 1 |
| Gościmski, A | 1 |
| Matras, J | 1 |
| Meneghelli, UG | 1 |
| Boaventura, S | 1 |
| Moraes-Filho, JP | 1 |
| Leitão, O | 1 |
| Ferrari, AP | 1 |
| Almeida, JR | 1 |
| Magalhães, AF | 1 |
| Castro, LP | 1 |
| Haddad, MT | 1 |
| Tolentino, M | 1 |
| Jorge, JL | 1 |
| Silva, E | 1 |
| Maguilnik, I | 1 |
| Mulder, CJ | 1 |
| Westerveld, BD | 1 |
| Smit, JM | 1 |
| Oudkerk Pool, M | 1 |
| Otten, MH | 1 |
| Tan, TG | 1 |
| van Milligen de Wit, AW | 1 |
| de Groot, GH | 1 |
| Fardet, L | 1 |
| Izzedine, H | 1 |
| Ciroldi, M | 1 |
| Tiev, KP | 1 |
| Cabane, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD[NCT00325676] | Phase 4 | 639 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis[NCT01733810] | 12 participants (Actual) | Interventional | 2013-02-01 | Completed | |||
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Diseas[NCT00300755] | Phase 3 | 60 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239] | Phase 3 | 14 participants (Anticipated) | Interventional | 2015-02-28 | Not yet recruiting | ||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488] | Phase 4 | 6 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study) | ||
| Study of a Dietary Supplement for Reflux During Sleep[NCT02274636] | 50 participants (Anticipated) | Interventional | 2014-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Healed EE was defined as a modified Hetzel-Dent (HD) score <2 on endoscopy at end of study. HD is a standardized rating scale for grading esophageal damage and severity of gastroesophageal reflux disease (GERD). HD score ranges from 0 (normal mucosa) to 4 (deep peptic ulceration). (NCT00300755)
Timeframe: 8 weeks
| Intervention | patients (Number) |
|---|---|
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | 0 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 2 |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | 2 |
Selected symptoms of GERD were assessed using a parent-administered questionnaire. The score for each symptom ranged from 0 (no symptom) to 3 (highest frequency of symptom), The weekly mean score was the sum of daily scores that week, divided by the number of days with scores for that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||
|---|---|---|---|---|---|
| Vomiting/regurgitation | Choking/gagging | Refusal to eat | Difficulty swallowing | Abdominal/belly pain | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | -0.25 | -0.47 | -0.26 | -0.39 | -0.28 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | -0.77 | -0.43 | -0.34 | -0.42 | -0.42 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | -0.06 | -0.05 | -0.16 | -0.13 | -0.24 |
Individual respiratory symptoms weekly score was calculated as the average score / number of events for a patient in the corresponding week if the patient answered a question ≥3 times that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Presence of cold or fever: scale 1=yes 0=no | Cough without cold: scale 1=yes 0=no | Noisy breathing: scale 0(none)-3(most of the time) | Noisy breathing on exhale: scale 1=yes 0=no | Wheezing or whistling sound: scale 1=yes 0=no | Noisy breathing on inhale: scale 1=yes 0=no | Croupy or barky sound: scale 1=yes 0=no | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | 0.11 | -0.24 | -0.16 | -0.16 | -0.02 | -0.16 | -0.13 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | 0.11 | -0.38 | -0.48 | -0.11 | -0.15 | -0.11 | -0.09 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 0.13 | -0.20 | -0.19 | -0.15 | -0.04 | -0.16 | -0.03 |
WGSS is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final week was defined as the last 7 days of symptom scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 1 Change from Baseline | Week 2 Change from Baseline | Week 3 Change from Baseline | Week 4 Change from Baseline | Week 5 Change from Baseline | Week 6 Change from Baseline | Week 7 Change from Baseline | Week 8 Change from Baseline | Final Week Change from Baseline | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | -0.47 | -1.24 | -1.38 | -1.32 | -1.30 | -1.42 | -1.58 | -1.61 | -1.66 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | -0.89 | -1.11 | -1.31 | -1.84 | -2.05 | -1.99 | -2.44 | -2.34 | -2.37 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 0.02 | -0.11 | -0.16 | -0.20 | -0.48 | -0.61 | -0.58 | -0.60 | -0.64 |
7 reviews available for pantoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; | 2006 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
The changing role of H2-receptor antagonists in acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1996 |
Pantoprazole--a third proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme I | 1997 |
Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis, Peptic; Gas | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
38 trials available for pantoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastro | 2013 |
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; An | 2009 |
Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Res | 2009 |
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Body Mass Index; Dose-Response Relationship, D | 2010 |
Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Canada; Child; Child, Preschool; Delayed-Action Pre | 2010 |
Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Double-Blind Metho | 2012 |
Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Ulcer Agents; Benzim | 2003 |
Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Confidence Intervals; Do | 2003 |
Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Metho | 2003 |
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Dru | 2005 |
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents | 2006 |
[Financial restrictions in health care systems could affect treatment quality of GERD-patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cost Contro | 2006 |
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aluminum Hydroxide; Analysis o | 2006 |
Effect of pantoprazole in older patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, | 2007 |
A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Humans; Inf | 2008 |
A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Double-Blin | 1995 |
Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Double-Blind Method; Esophagitis, Peptic; F | 1995 |
Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1996 |
Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole--comparison of 24-hour intragastric and oesophageal pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Enzyme Inhibito | 1997 |
One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz | 1997 |
Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1998 |
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Double-Blind Method; Enzyme In | 1999 |
Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1999 |
Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1999 |
Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Fem | 1999 |
Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2000 |
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Dose-Respon | 2000 |
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Do | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2001 |
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans; | 2002 |
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzi | 2002 |
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre t
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz | 2002 |
25 other studies available for pantoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Impact of age on laryngopharyngeal reflux disease presentation: a multi-center prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Esophageal pH Monitoring; Esophag | 2017 |
Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Eosinophils; Esophagitis, Peptic; Esophagus; Female | 2016 |
Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Drug Administration | 2009 |
Gastro-oesophageal reflux disease in an obese patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastroesoph | 2009 |
Chronic cough--about a clinical case...
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chronic Disease; Cough; Esophagitis, Pep | 2009 |
[Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2010 |
Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alcoholism; Anorexia; Anti-Inflammatory Agents | 2011 |
CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; | 2012 |
[Panum (pantoprazole) effectiveness in the treatment of patients with GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Algorithms; Esophagitis, Peptic; F | 2011 |
Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esophagitis, Peptic; Female; Gastric Mucosa; Helicob | 2012 |
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroeso | 2012 |
[Proton pump inhibitor in reflux disease. Administer for maximum effect from the beginning].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Dose-Response Rel | 2002 |
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Stability; Drug Sto | 2002 |
[Graded therapy in reflux disease. "In severe cases 40 mg., in milder 20 mg."].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
GERD 2003: issues from the past and a consensus for the future.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 2004 |
[Treatment of reflux esophagitis by Xuanfu Daizhe Decoction combined with pantoprazole or omeprazole: a comparative study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Drug Therapy, Combination; Eso | 2003 |
Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agen | 2004 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pe | 2005 |
Balanced perspective essential in erosive oesophagitis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2005 |
Inlet patch presenting with food impaction caused by peptic stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Biopsy; Catheterization; Deglutiti | 2007 |
[Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Hum | 1996 |
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Benzimidazoles; Bile Reflux; Case-Contro | 2001 |
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimid | 2001 |
Pantoprazole-induced recurrent anaphylactic shock.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anaphylaxis; Benzimidazoles; Esophagitis, Peptic; Hu | 2002 |